RATIONALE: Immunotherapy is a promising treatment for food allergy with oral (OIT) and epicutaneous (EPIT) immunotherapy protocols being investigated in late-phase clinical trials. There is increasing evidence that molecular mechanisms differ between the two types of immunotherapy. In this study, we investigated the kinetics of miRNA expression patterns underlying the therapeutic effect of EPIT and OIT. METHODS: BALB/c mice were orally sensitized to peanut and treated with EPIT, OIT or not treated (sham). Mice (n5168) were sacrificed during treatment at 1,2,4,6 and 8 weeks; and 8 weeks after the end of treatment. MiRNAs were analysed in sorted splenic CD4 + cells using high-throughput sequencing on a HiSeq4000 and validated in an independent experiment (n584) by LNA-enhanced qPCRs. RESULTS: Global miRNAprofiles reproducibly distinguished EPITtreated mice from controls and/or OIT-treated mice early after initiation of treatment. Up to 200 MiRNAs were found differentially expressed (p adj <0.05) between protocols with a large overlap of miRNAs between adjacent time points. miRNAs common to both immunotherapy protocols included miRNAs controlling T cell differentiation and function (e.g.,miR-24-3p and miR-193b-3p), but most miRNA changes were specific to each protocol. Notably, expression changes of miRNAs previously associated with allergy and asthma including the paradigmatic anti-Inflammomir miR-146a/b-5p were only detected in EPIT treated animals. CONCLUSIONS: Immunotherapy leads to early and reproducible changes in miRNA expression specific for OIT or EPIT respectively, shortly after the initiation of treatment. Our study provides further evidence for diverging molecular alterations underlying different immunotherapy protocols pointing to different molecular mechanisms of action. is being developed as a SCIT for the treatment of peanut allergy and its safety and tolerability is being investigated in adult and pediatric patients in 7 sites in the USA and Canada. HAL-MPE1 would be administered in a controlled setting, similar to what is being done with other SCIT products. METHODS: This is a randomized, double-blind, placebo-controlled study in 42 patients with documented medical history of systemic reactions after peanut ingestion, a skin prick test to peanut >3mm, serum specific anti-peanut IgE >5.0kU/L and Arah2 IgE >2.0kU/L. Twelve adult patients, 15 adolescents and 15 children will be included. HAL-MPE1 or placebo (2:1 ratio) is administered weekly and gradually up-dosed to the maximum dose of 375 mg modified peanut protein (repeated two times) during 16-21 weeks. The safety and tolerability of HAL-MPE1 is assessed by evaluating the local and systemic allergic reactions and other adverse events. RESULTS: Treatment of the adult cohort is completed. 11 out of 12 adults (92%) reached the maximum dose. The adolescent and children cohorts are currently ongoing. Enrollment of the adolescent cohort has been completed and the enrollment of children is ongoing. CONCLUSIONS: A SCIT treatment with a modified peanut extract is being developed for the treatment of peanut allergy. Its safety and tolerability have been assessed in adults and based on positive safety and tolerability results, the treatment is now being investigated in pediatric patients.
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